[{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ SLR Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ SLR Capital Partners"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Ardelyx","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Ardelyx"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Ardelyx","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ardelyx \/ Ardelyx","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Ardelyx"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Ardelyx","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Ardelyx"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.13,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Ardelyx","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0.52000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.52000000000000002,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Ardelyx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Neurology","graph2":"Phase II","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ardelyx \/ Ardelyx","highestDevelopmentStatusID":"8","companyTruncated":"Ardelyx \/ Ardelyx"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Ardelyx","highestDevelopmentStatusID":"8","companyTruncated":"Ardelyx \/ Ardelyx"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"RDX013","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ardelyx \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Ardelyx
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
